CAMBRIDGE, Mass., June 27,
2024 /PRNewswire/ -- Akebia Therapeutics®,
Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose
to better the lives of people impacted by kidney disease, today
announced that John Butler, Chief
Executive Officer, will participate in the H.C. Wainwright
3rd Annual Kidney Virtual Conference on Monday, July 15, 2024. Mr. Butler will present at
9:30 a.m. ET to provide updates on
the progress of commercial launch activities for Vafseo®
(vadadustat) Tablets.
A webcast of the presentation can be accessed through the
"Investors" section of Akebia's website at https://ir.akebia.com
for 30 days following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. Akebia was
founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-hc-wainwright-3rd-annual-kidney-virtual-conference-302184495.html
SOURCE Akebia Therapeutics, Inc.